Browsing Tag
Novo Nordisk
103 posts
U.S. stock market top losers: Globant, Newegg, Doximity, and Applied Materials among biggest decliners
Explore the full list of U.S. stock market’s biggest losers on May 16, 2025. Find out why Globant, Doximity, and 19 other stocks fell amid rising market uncertainty.
Novo Nordisk and Septerna forge $2.2bn GPCR deal to develop oral therapies for obesity and diabetes
Novo Nordisk partners with Septerna in a $2.2B deal to develop oral GPCR therapies for obesity and diabetes. Explore the full stock sentiment and deal impact.
Eli Lilly’s oral weight-loss pill shakes Novo Nordisk as investors brace for market shift
Novo Nordisk shares drop after Eli Lilly’s oral weight-loss pill shows promise. Analysts see a shifting obesity drug market. What this means for investors.
Novo Nordisk’s Mim8 shows promising efficacy and safety in haemophilia A children, phase 3 interim results reveal
Novo Nordisk A/S has announced encouraging interim results from its phase 3 FRONTIER3 clinical trial, highlighting the potential…
Novo Nordisk’s Amycretin outshines rivals in weight-loss drug trials
Novo Nordisk has achieved a critical milestone in the fight against obesity, reporting highly promising results from an…
Novo Nordisk’s semaglutide 7.2 mg sets new standard in obesity treatment with STEP UP trial results
Novo Nordisk, a leader in chronic disease care, has unveiled compelling results from its STEP UP obesity trial.…
Novo Nordisk and Valo Health expand AI partnership to tackle cardiometabolic diseases
Novo Nordisk and Valo Health have strengthened their collaboration to advance AI-driven drug discovery, targeting major cardiometabolic diseases,…
Novo Nordisk’s CagriSema demonstrates superior weight loss results in REDEFINE 1 trial
Novo Nordisk A/S has unveiled significant findings from its REDEFINE 1 trial, marking a major advancement in the…
Novo Nordisk set to finalize $11bn acquisition of Catalent manufacturing sites
Novo Nordisk is set to finalise its acquisition of three Catalent manufacturing sites, marking a pivotal step in…
Hims & Hers’ earnings soar while GLP-1 drug crisis deepens—what this means for investors
Hims & Hers Health Inc. saw its stock surge following a robust quarterly earnings report, which showcased significant…